Submit Deal

BEIGENE LTD

Summary

BeiGene is a global, commercial-stage, research-based biotechnology company focused on molecularly-targeted and immuno-oncology cancer therapeutics.

Deals Overview

Total Deals4

Valued Deals3

Total Value£ 3.85 B

Avg. Deal Size£ 1.28 B

Market Context

Senior Management

Howard Liang
CFO & CSO
John V. Oyler
Chairman
Vivian Ni
Communications Director

Sort

07 Mar 2017|Hong Kong|Biotechnology

Target: BEIGENE BIOLOGICS CO LTD

Bidder: GUANGZHOU DEVELOPMENT DISTRICT

2 Service Providers

2 Bidder

3 Dealmakers

3 Bidder

n/a

Value

31 Oct 2019|China|Biotechnology

Target: BEIGENE LTD

Bidder: AMGEN INC

8 Service Providers

5 Target | 3 Bidder

29 Dealmakers

7 Target | 22 Bidder

£ 2.10 B

Value

12 Jul 2020|China|Biotechnology

Target: BEIGENE LTD

Bidder: AMGEN INC

3 Service Providers

1 Target | 2 Bidder

6 Dealmakers

1 Target | 5 Bidder

£ 1.65 B

Value

02 Nov 2021|United States|Biotechnology

Target: SHORELINE BIOSCIENCES

Bidder: EVENTIDE ASSET MANAGEMENT

4 Service Providers

2 Target | 2 Bidder

5 Dealmakers

2 Target | 3 Bidder

£ 102 M

Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy

Senior Management

Howard Liang
CFO & CSO
John V. Oyler
Chairman
Vivian Ni
Communications Director